---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-055521"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:58:32.898462+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics launches LYTENAVA (bevacizumab gamma) in Germany and UK for wet AMD

## Summary
- Commercial launch of LYTENAVA (bevacizumab gamma) in Germany and UK announced on June 2, 2025.
- Indication: treatment of wet age-related macular degeneration (wet AMD).
- First approved bevacizumab gamma product for wet AMD in these two markets.

## SEC filing metadata
- accession: 0001104659-25-055521
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465925055521/0001104659-25-055521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465925055521/tm2516951d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-055521
- JSON: https://secwatch.observer/filing/0001104659-25-055521.json
- Plain text: https://secwatch.observer/filing/0001104659-25-055521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.